GlassScriptPhysician profile
Kevin T Farthing
NPI 1629424429
$6,408.61
in general payments reported to CMS, 2019-2025
37 companies · $745 in 2025
The $745 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $962 · 2021: $1,158 · 2022: $1,142 · 2023: $1,085 · 2024: $1,161 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,946 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,945.70 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,868.12 | 2021-2025 | |
| Lilly USA, LLC | $811.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $520.86 | 2019-2025 | |
| Glaxosmithkline, LLC. | $458.93 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biogen, INC. | $320.82 | 2022-2025 | Vumerity, Tysabri, Leqembi |
| Biohaven Pharmaceutical Holding Company LTD. | $271.53 | 2022 | |
| Amgen INC. | $268.35 | 2020-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $209.48 | 2020-2023 | Farxiga |
| Biohaven Pharmaceuticals, INC. | $205.98 | 2021 | |
| Astellas Pharma US INC | $164.51 | 2020-2021 | |
| Novo Nordisk INC | $127.83 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $120.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.63 | 2020-2022 | |
| Daiichi Sankyo INC. | $93.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.34 | 2020-2024 | Jardiance |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $72.24 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.00 | 2021-2023 | |
| Abbott Laboratories | $64.75 | 2023-2025 | Freestyle Libre 3, Infinity |
| Sk Life Science, INC. | $62.87 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $61.01 | 2019-2025 | Spravato |
| Livanova USA, INC. | $50.54 | 2020-2022 | |
| Lundbeck LLC | $49.56 | 2020-2025 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.59 | 2021-2024 | Xifaxan |
| Allergan, INC. | $34.48 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $32.30 | 2019-2020 | |
| Emd Serono, INC. | $28.11 | 2023 | Mavenclad |
| Idorsia Pharmaceuticals US INC | $27.66 | 2023 | Quviviq |
| Ucb, INC. | $25.89 | 2021 | |
| Boston Scientific Corporation | $21.78 | 2024 | Watchman Flx |
| Kyowa Kirin, INC. | $20.25 | 2020 | |
| Corcept Therapeutics | $17.52 | 2025 | Korlym |
| Eisai INC. | $17.48 | 2023 | |
| Adamas Pharmaceuticals, INC. | $16.88 | 2021 | |
| Redhill Biopharma INC. | $16.61 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.81 | 2021 | |
| Neurocrine Biosciences, INC. | $13.43 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Farthing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.